GlassScriptPhysician profile
Onyebuchi Ogbo
NPI 1982247524
$5,385.94
in general payments reported to CMS, 2019-2025
18 companies · $2,154 in 2025
The $2,154 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.03 · 2022: $300 · 2023: $1,789 · 2024: $1,111 · 2025: $2,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,876 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,875.99 |
| Education | $177.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $896.57 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $629.13 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $585.15 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $569.34 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $561.17 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $464.27 | 2023-2025 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $383.18 | 2024-2025 | Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $342.33 | 2024-2025 | Auvelity |
| Lundbeck LLC | $260.01 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $244.26 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $105.76 | 2022-2023 | Trintellix |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $77.79 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $69.13 | 2025 | Fanapt |
| Indivior INC. | $68.52 | 2024-2025 | Sublocade |
| Braeburn INC. | $46.50 | 2024-2025 | Brixadi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $32.03 | 2021 | |
| Tempus Ai, INC | $27.19 | 2024 | |
| Sage Therapeutics, LLC | $23.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Onyebuchi Ogbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.